Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ST PETER PORT, Guernsey and LONDON, July 6 /PRNewswire/ --

- GBP13.1 Million Funding to Drive Novel Antibiotics Platform Addressing Areas of Major Unmet Need, Including Hospital Acquired Infections C. Difficile and MRSA

Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP ("CP2"), today announces its investment in a majority shareholding in Novacta Biosystems Limited ("Novacta"), which is developing a portfolio of antibiotics. The total being raised is GBP13.1m ($21.6m), payable against pre-agreed milestones. As part of this investment certain existing investors are re-investing.

Novacta is a UK-based company developing novel, naturally-derived products known as 'lantibiotics' as potential drugs. Lantibiotics have potent anti-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed through its proprietary technology platform. The most advanced programme will enter the clinic next year to treat infections caused by Clostridium difficile ("C. difficile"). The Wellcome Trust has provided in the order of GBP4m of translational funding to Novacta since 2004 for the development of the platform technology and more recently the C. difficile programme.

New anti-infective drugs are needed to target C. difficile without depleting other beneficial bacteria in the gut and preclinical data show that Novacta's lead lantibiotics selectively kill C. difficile with less disturbance of normal gut bacteria than seen with existing drugs. C. difficile infections (CDIs) are a serious problem: the number of cases grew by 22 percent in the UK last year, accounting for twice as many deaths as MRSA.

Novacta's pipeline also includes programmes targeting other areas of unmet medical need in bacterial infection. These include novel prom
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Santa Paula, CA (PRWEB) September 15, 2014 ... of long term implantable silicones for the medical ... strength, responsive silicone gel for the implantable medical ... incorporates a unique crosslink technology delivering a silicone ... adhesion. The Dual Matrix technology consists of ...
(Date:9/15/2014)... September 15, 2014 Hydro Dynamics, ... announced today that it will be partnering with ... ( http://www.proteaf.com ) for implementing its Shock Wave ... continuous processing. Continuous flow chemistry through process ... pharmaceutical and petrochemical markets for decades. The ...
(Date:9/12/2014)... magnet using an electric field (magnetoelectric memory [MEM] ... next-generation technology for information processing and storage. Multiferroic ... due to the coexistence of electric and magnetic ... spontaneous electric and magnetic polarizations is rare in ... the MEM effect. This article briefly reviews a ...
(Date:9/12/2014)... -- On Thursday, September 11, 2014, the NASDAQ ... Average finished the day 0.12% lower at 17,049.00, and the ... broad based as seven out of ten sectors ended the ... ended the day at 741.83, down 0.33%, while the index ... initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Oct. 31, 2011 Reportlinker.com announces that ... in its catalogue: US ... http://www.reportlinker.com/p0397796/US-Intranasal-Drug-Delivery-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology This report ... Delivery in US$ Million by the following ...
... iBio, Inc. (NYSE AMEX: IBIO ) ... Patent and Trademark Office for US Patent 8,058,511, entitled ... extends iBio,s patent coverage of viral vectors comprising its ... developed by scientists at iBio,s research collaborator, the Fraunhofer ...
... BETHESDA, Md., Oct. 28, 2011 , ... innovator in biotechnology for therapy in diabetes, metabolic syndrome ... services to food, supplement, biotechnology and pharmaceutical companies – ... sell $1.25 million of shares of its common stock ...
Cached Biology Technology:US Intranasal Drug Delivery Industry 2US Intranasal Drug Delivery Industry 3US Intranasal Drug Delivery Industry 4US Intranasal Drug Delivery Industry 5US Intranasal Drug Delivery Industry 6US Intranasal Drug Delivery Industry 7US Intranasal Drug Delivery Industry 8US Intranasal Drug Delivery Industry 9US Intranasal Drug Delivery Industry 10iBio Announces New US Patent for iBioLaunchâ„¢ Technology 2iBio Announces New US Patent for iBioLaunchâ„¢ Technology 3Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 2Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 3
(Date:9/15/2014)... carbon-halogen bonds are produced naturally across all kingdoms of ... with a broad range of biological activities. The presence ... profound influence on their molecular properties. , ... been to find the late-stage, site-specific incorporation of a ... an sp C-H bond (one of the most inert ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Research suggests that genes that affect hearing and cognitive ... the ability to understand and perceive rhythm, pitch, timbre, ... authors of a BioEssays article explain that ... within a population, with the majority of individuals having ... a complex trait attributable to several underlying genes, and ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... about Arctic climate variation during an ancient episode of ... climate variability in the greenhouse world of the Late ... probably would not greatly change the climatic influence associated ... the El Nio Southern Oscillation (ENSO) or ...
... Springer journals Frontiers of Medicine and Protein ... important literature database for medical and biomedical articles, in January. ... publishing partner Higher Education Press. Both journals are part of ... 90 Springer journals. Frontiers in Medicine has a ...
... Ancient stone faces carved into the walls of a well-known ... searching for fossils of extinct giant rats., The team of archaeologists ... tip of East Timor. "Looking up from the cave floor ... on what seemed to be a weathered carving," CSIRO,s Dr Ken ...
Cached Biology News:Arctic climate variation under ancient greenhouse conditions 2Arctic climate variation under ancient greenhouse conditions 3Research literature from China listed in Medline 2Giant rats lead scientists to ancient face carvings 2
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: